Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To estimate the impact of global strategies, such as pooled procurement arrangements, third-party price negotiation and differential pricing, on reducing the price of antiretrovirals (ARVs), which currently hinders universal access to HIV/AIDS treatment. METHODS: We estimated the impact of global strategies to reduce ARV prices using data on 7253 procurement transactions (July 2002-October 2007) from databases hosted by WHO and the Global Fund to Fight AIDS, Tuberculosis and Malaria. FINDINGS: For 19 of 24 ARV dosage forms, we detected no association between price and volume purchased. For the other five ARVs, high-volume purchases were 4-21% less expensive than medium- or low-volume purchases. Nine of 13 generic ARVs were priced 6-36% lower when purchased under the Clinton Foundation HIV/AIDS Initiative (CHAI). Fifteen of 18 branded ARVs were priced 23-498% higher for differentially priced purchases compared with non-CHAI generic purchases. However, two branded, differentially priced ARVs were priced 63% and 73% lower, respectively, than generic non-CHAI equivalents. CONCLUSION: Large purchase volumes did not necessarily result in lower ARV prices. Although current plans for pooled procurement will further increase purchase volumes, savings are uncertain and should be balanced against programmatic costs. Third-party negotiation by CHAI resulted in lower generic ARV prices. Generics were less expensive than differentially priced branded ARVs, except where little generic competition exists. Alternative strategies for reducing ARV prices, such as streamlining financial management systems, improving demand forecasting and removing barriers to generics, should be explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nunn, A. S., Fonseca, E. M., Bastos, F. I., Gruskin, S., & Salomon, J. A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040305 · Cited by 142
Cited by
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661
Snakebite envenoming from a global perspective: Towards an integrated approach
Gutiérrez, J. M., Williams, D., Fan, H. W., & Warrell, D. A. (2010) · Toxicon · doi:10.1016/j.toxicon.2009.11.020 · Cited by 355
Driving a decade of change: HIV/AIDS, patents and access to medicines for all
Hoen, E. '., Berger, J., Calmy, A., & Moon, S. (2011) · Journal of the International AIDS Society · doi:10.1186/1758-2652-14-15 · Cited by 334
“First, competitive production of medicines has consistently proven to be the most powerful and reliable way to reduce drug prices to their lowest sustainable levels [67,89].”
BackgroundConstraints and challenges in access to insulin: a global perspective
Beran, D., Ewen, M., & Laing, R. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00521-5 · Cited by 186
Cameron, A., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Laing, R. O. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.004 · Cited by 177
Metadata
- Authors
- Waning, B.
- Venue
- Bulletin of the World Health Organization
- Publisher
- WHO Press
- Published
- 2009-07-01
- Volume
- 87
- Issue
- 7
- Pages
- 520-528
- ISSN
- 0042-9686 (ISSN-L)
- OpenAlex
- W1967855332
- Cited by
- 122
- References
- 1
- FWCI
- 28.85
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.